# Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

> **NCT00803062** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 452 (actual)

## Conditions studied

- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Cervical Squamous Cell Carcinoma
- Recurrent Cervical Carcinoma
- Stage IVB Cervical Cancer

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Cisplatin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Topotecan Hydrochloride

## Key facts

- **NCT ID:** NCT00803062
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 452 (ACTUAL)
- **Last updated:** 2019-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00803062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00803062, "Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00803062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*